Contributions of protein phosphatases PP1, PP2A, PP2B, and PP5 to the regulation of tau phosphorylation. Euro J Neurosci

Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314, USA.
European Journal of Neuroscience (Impact Factor: 3.67). 11/2005; 22(8):1942-50. DOI: 10.1111/j.1460-9568.2005.04391.x
Source: PubMed

ABSTRACT Abnormal hyperphosphorylation of tau is believed to lead to neurofibrillary degeneration in Alzheimer's disease (AD) and other tauopathies. Recent studies have shown that protein phosphatases (PPs) PP1, PP2A, PP2B and PP5 dephosphorylate tau in vitro, but the exact role of each of these phosphatases in the regulation of site-specific phosphorylation of tau in the human brain was unknown. Hence, we investigated the contributions of these PPs to the regulation of tau phosphorylation quantitatively. We found that these four phosphatases all dephosphorylated tau at Ser199, Ser202, Thr205, Thr212, Ser214, Ser235, Ser262, Ser396, Ser404 and Ser409, but with different efficiencies toward different sites. The K(m) values of tau dephosphorylation catalysed by PP1, PP2A and PP5 were 8-12 microm, similar to the intraneuronal tau concentration of human brain, whereas the K(m) of PP2B was fivefold higher. PP2A, PP1, PP5 and PP2B accounted for approximately 71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain. The total phosphatase activity and the activities of PP2A and PP5 toward tau were significantly decreased, whereas that of PP2B was increased in AD brain. PP2A activity negatively correlated to the level of tau phosphorylation at the most phosphorylation sites in human brains. Our findings indicate that PP2A is the major tau phosphatase that regulates its phosphorylation at multiple sites in human brain. The abnormal hyperphosphorylation of tau is partially due to a downregulation of PP2A activity in AD brain.

Download full-text


Available from: Cheng-Xin Gong, Aug 27, 2015
1 Follower
  • Source
    • "Several protein kinases, such as glycogen synthase kinase-3b (GSK-3b), extracellular signal-regulated kinases (ERK1/2), cyclin dependent kinases 5 (CDK5), cAMP-dependent protein kinase (PKA), calcium/calmodulin-dependent protein kinase II (CaMK-II), and JNKs, have been implicated in hyperphosphorylation of tau in AD (Gong et al. 2010). Tau phosphorylation is also regulated by protein phosphatase 2A (PP2A) (Gong et al. 2000), which accounts for over 70 % of total tau 104 Cell Mol Neurobiol (2015) 35:101–110 123 Author's personal copy phosphatase activity in the mammalian brain (Liu et al. 2005). Increased tau hyperphosphorylation with concurrent activation of GSK-3b, CDK5, and CaMK-II, as well as inhibition of PP2A is observed in a rat model of CCH, which shows spatial learning/memory deficits (Yao et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic cerebral hypoperfusion (CCH) is a common consequence of various cerebral vascular disorders and hemodynamic and blood changes. Recent studies have revealed an important role of CCH in neurodegeneration and dementia, including vascular dementia and Alzheimer's disease (AD). This article reviews the recent advances in understanding CCH-induced neurodegeneration and AD-related brain pathology and cognitive impairment. We discuss the causes and assessment of CCH, the possible mechanisms by which CCH promotes Alzheimer-like pathology and neurodegeneration, and animal models of CCH. It appears that CCH promotes neurodegeneration and AD through multiple mechanisms, including induction of oxidative stress, Aβ accumulation and aggravation, tau hyperphosphorylation, synaptic dysfunction, neuronal loss, white matter lesion, and neuroinflammation. Better understanding of the mechanisms of CCH will help develop therapeutic strategies for preventing and treating neurodegeneration, including sporadic AD and vascular dementia, caused by CCH.
    Cellular and Molecular Neurobiology 10/2014; 35(1). DOI:10.1007/s10571-014-0127-9 · 2.20 Impact Factor
  • Source
    • "In AD, total phosphatase activity is reduced by approximately 50% (Liu et al, 2005). PPP2CA is the most efficient phosphatase acting on hyperphosphorylated tau (Liu et al, 2005). Although previous studies reported direct regulation of PPP2CA by miR-125b (Le et al, 2011), PPP2CA protein levels are not downregulated upon miR-125b overexpression in primary rat neurons under our conditions (Fig 3A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sporadic Alzheimer's disease (AD) is the most prevalent form of dementia, but no clear disease-initiating mechanism is known. Aβ deposits and neuronal tangles composed of hyperphosphorylated tau are characteristic for AD. Here, we analyze the contribution of microRNA-125b (miR-125b), which is elevated in AD. In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains. These data implicate miR-125b in the pathogenesis of AD by promoting pathological tau phosphorylation.
    The EMBO Journal 07/2014; 33(15). DOI:10.15252/embj.201387576 · 10.75 Impact Factor
  • Source
    • "As much as 40% of the abnormally hyperphosphorylated tau is cytosolic in AD brains (Kopke et al., 1993), and intraneuronal Ab accumulation precedes plaque deposition (Bancher et al., 1989; Cataldo et al., 2004; Grundke-Iqbal et al., 1989; Mori et al., 2002) and is correlated with neuronal cell death in AD transgenic mouse models (Espana et al., 2010; Gandy et al., 2010; Oddo et al., 2003). Phosphoprotein phosphatase 2A (PP2A) accounts for w70% of the total phospho-tau phosphatase activity in healthy human brain (Bennecib et al., 2000; Gong et al., 1993, 1995, 2000; Liu et al., 2005) and also functions to dephosphorylate the Ab precursor protein (APP) so as to reduce the formation of the Ab (Sontag et al., 2007). In "
    [Show abstract] [Hide abstract]
    ABSTRACT: A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2(PP2A), or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.
    Neurobiology of Aging 06/2014; 35(12). DOI:10.1016/j.neurobiolaging.2014.06.012 · 4.85 Impact Factor
Show more